Canaccord raised the firm’s price target on Corcept Therapeutics to $35 from $34 and keeps a Buy rating on the shares. The firm said strong Korlym revenues have led to a new inflection of growth and they believe the net sales of Korlym will continue to grow through 2024 until the transition between Korlym and relacorilant begins, if the latter is approved.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CORT:
- Corcept Therapeutics price target raised to $34 from $32 at Canaccord
- Corcept Therapeutics price target raised to $31 from $27 at Piper Sandler
- Corcept Therapeutics price target raised to $47.50 from $44 at Ladenburg
- Corcept Therapeutics price target raised to $32 from $30 at H.C. Wainwright
- Corcept Therapeutics reports Q2 EPS 25c, consensus 15c